Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
National Institute for Health and Care Excellence (NICE) June 14, 2016 – Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR) External Web Site Policy: The U.S. Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for th...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publishing House Zaslavsky
2016-10-01
|
| Series: | Počki |
| Online Access: | http://kidneys.zaslavsky.com.ua/article/view/84326 |